SEL 068

Drug Profile

SEL 068

Alternative Names: Immunomodulatory nanoparticle vaccine for smoking cessation - Selecta Biosciences; SEL-068; tSVP™ for smoking cessation and relapse prevention - Selecta Biosciences

Latest Information Update: 16 Jul 2016

Price : $50

At a glance

  • Originator Selecta Biosciences
  • Class Drug withdrawal therapies; Smoking cessation therapies; Vaccines
  • Mechanism of Action Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No

Highest Development Phases

  • No development reported Smoking withdrawal

Most Recent Events

  • 16 Jul 2016 No recent reports of development identified for phase-I development in Smoking-withdrawal(Prevention of relapse, In volunteers) in Belgium (SC, Injection)
  • 06 May 2014 Selecta Biosciences completes a phase I trial in in volunteers for Smoking withdrawal in Belgium (NCT01478893)
  • 21 Nov 2011 Phase-I clinical trials in Smoking withdrawal in Belgium (SC)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top